Literature DB >> 25306465

Synthesis, molecular docking and biological evaluation of coumarin derivatives containing piperazine skeleton as potential antibacterial agents.

She-Feng Wang1, Yong Yin1, Xun Wu1, Fang Qiao1, Shao Sha1, Peng-Cheng Lv1, Jing Zhao1, Hai-Liang Zhu2.   

Abstract

A series of 4-hydroxycoumarin derivatives were designed and synthesized in order to find some more potent antibacterial drugs. Their antibacterial activities against Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis and Staphylococcus aureus were tested. These compounds showed good antibacterial activities against Gram-positive strains. Compound 4 g represented the most potent antibacterial activity against Bacillus subtilis and S. aureus with MIC of 0.236, 0.355 μg/mL, respectively. What's more, it showed the most potent activity against SaFabI with IC50 of 0.57 μM. Molecular docking of 4 g into S. aureus Enoyl-ACP-reductase active site were performed to determine the probable binding mode, while the QSAR model was built to check the previous work as well as to introduce new directions.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3D-QSAR; Antibacterial activities; Coumarin derivatives; Molecular docking; SaFabI

Mesh:

Substances:

Year:  2014        PMID: 25306465     DOI: 10.1016/j.bmc.2014.09.048

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

Review 1.  Coumarin-piperazine derivatives as biologically active compounds.

Authors:  Kinga Ostrowska
Journal:  Saudi Pharm J       Date:  2019-12-07       Impact factor: 4.330

2.  Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies.

Authors:  Santiago García; Itzel Mercado-Sánchez; Luis Bahena; Yolanda Alcaraz; Marco A García-Revilla; Juvencio Robles; Nancy Santos-Martínez; David Ordaz-Rosado; Rocío García-Becerra; Miguel A Vazquez
Journal:  Molecules       Date:  2020-11-04       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.